Pacira Partners with Molteni to Expand EXPAREL’s Reach in Europe
Event summary
- Pacira BioSciences has signed an exclusive deal with Molteni Farmaceutici to commercialize EXPAREL in the EU and UK.
- Molteni will handle regulatory, market access, and commercialization efforts, with Pacira manufacturing the product.
- First commercial sales are expected in 2027, starting in Italy, Germany, Austria, and Poland.
- Pacira will receive an undisclosed upfront payment, supply price, and royalties on future sales.
- The partnership aligns with Pacira’s 5x30 growth strategy and Molteni’s expansion plans.
The big picture
This deal extends Pacira’s opioid-sparing pain management strategy into Europe, a region with significant unmet needs in postsurgical care. Molteni’s established presence in pain management could accelerate EXPAREL’s adoption, but success hinges on regulatory approvals and commercial execution. The partnership also reflects a broader industry shift toward non-opioid solutions amid growing global scrutiny of opioid use.
What we're watching
- Market Penetration
- Whether Molteni can effectively leverage its European network to drive EXPAREL adoption.
- Regulatory Timing
- The pace at which Molteni secures approvals in key markets like Switzerland.
- Revenue Impact
- How royalties from European sales contribute to Pacira’s financial growth.
Related topics
